Up 308% in 6 months, why is the Mesoblast share price tumbling today?

The Mesoblast share price is taking a tumble on Monday. But why?

| More on:
Scientist looking at a laptop thinking about the share price performance.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price is sliding today.

Shares in the S&P/ASX 300 Index (ASX: XKO) biotech company closed on Friday trading for $1.15. In morning trade on Monday, they are changing hands for $1.135 apiece, down 1.3%.

For some context, the ASX 300 is down 0.7% at this same time.

Don't feel too bad for shareholders, though.

As you can see on the chart below, the Mesoblast share price has rocketed this year and remains up a whopping 308% over the past six months.

Here's what's happening today.

Clinical trial launch fails to boost Mesoblast share price

Following on the very strong run higher over recent months, today's pressure on the Mesoblast share price looks to be primarily related to the broader selling on the ASX and US markets rather than the company's announcement of a clinical trial launch.

On that trial front, Mesoblast said patient enrolment at multiple sites across the United States has commenced for the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product rexlemestrocel-L. That's intended for patients with chronic low back pain (CLBP) due to inflammatory degenerative disc disease of less than five years.

The United States Food and Drug Administration (FDA) has already confirmed the design of the 300-patient randomised, placebo-controlled trial and the 12-month primary endpoint of pain reduction as an approvable indication.

Key secondary measures include improvement in quality of life and function, as well as reduced opioid usage.

Commenting on the launch of the trial, whose results could offer ongoing support for the Mesoblast share price, Alan Miller, trial investigator at Coastal Health Specialty Care, said, "This therapy has the potential to be groundbreaking and life-changing for the low back pain population."

Mesoblast chief medical officer Eric Rose added:

We are very excited to be actively enrolling our pivotal trial of rexlemestrocel-L across multiple sites and look forward to confirming the durable pain reduction previously observed in the first Phase 3 trial.

There is a significant need for a safe, effective, and durable treatment in patients with CLBP and degenerative disc disease, in particular one that reduces or eliminates opioid use.

In a previous boost for the Mesoblast share price, the FDA designated rexlemestrocel-L, a Regenerative Medicine Advanced Therapy (RMAT) for the treatment of chronic low back pain.

Mesoblast notes that RMAT designation provides all the benefits of Breakthrough and Fast Track designations, including rolling review and eligibility for priority review on the filing of a Biologics License Application (BLA).

Stay tuned.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

Mesoblast shares have surged more than 1,000% over the last 12 months.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Earnings Results

ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

Read more »